MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-07-2025
ANI Pharmaceuticals Net Debt 2011-2026 | ANIP
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt ANI Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 166 M | 64.5 M | 238 M | 187 M | 178 M | 123 M | 140 M | 170 M | 93.3 M | -41.3 M | -58.3 M | -11.1 M | -26.9 M | -39.9 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 238 M | -58.3 M | 84.5 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M |  Germany |
 |
Alector
ALEC
|
-47.4 M | $ 2.13 | -12.55 % | $ 219 M |  USA |
 |
Acer Therapeutics
ACER
|
-2.08 M | - | 2.71 % | $ 14 M | USA |
 |
BioCardia
BCDA
|
212 K | $ 1.37 | 6.2 % | $ 29 M | USA |
 |
Black Diamond Therapeutics
BDTX
|
-14.3 M | $ 2.4 | -2.83 % | $ 132 M | USA |
 |
BioLineRx Ltd.
BLRX
|
-13.9 M | $ 2.8 | -1.06 % | $ 908 M |  Israel |
 |
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | USA |
 |
BioXcel Therapeutics
BTAI
|
73 M | $ 1.64 | -1.8 % | $ 4.16 M | USA |
 |
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | USA |
 |
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | USA |
 |
BeyondSpring
BYSI
|
-107 M | $ 1.44 | 6.3 % | $ 58.1 M | USA |
 |
Cabaletta Bio
CABA
|
-188 M | $ 3.34 | 0.6 % | $ 3.9 M | USA |
 |
AbCellera Biologics
ABCL
|
14.7 M | $ 3.7 | 2.49 % | $ 1.11 B |  Canada |
 |
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Codexis
CDXS
|
12.5 M | $ 1.05 | 3.47 % | $ 77.1 M | USA |
 |
Cerus Corporation
CERS
|
-6.33 M | $ 2.6 | 1.56 % | $ 480 M | USA |
 |
Certara
CERT
|
105 M | $ 7.17 | 1.27 % | $ 1.15 B | USA |
 |
Cullinan Management
CGEM
|
-80.9 M | $ 15.91 | 2.65 % | $ 931 M | USA |
 |
Compugen Ltd.
CGEN
|
-5.05 M | $ 2.28 | 25.97 % | $ 204 M | Israel |
 |
ARCA biopharma
ABIO
|
-60.6 M | - | 1052.0 % | $ 415 M | USA |
 |
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
-27.4 M | - | 4.01 % | $ 150 M | Canada |
 |
Coherus BioSciences
CHRS
|
-101 M | $ 1.66 | -0.9 % | $ 156 M | USA |
 |
Adverum Biotechnologies
ADVM
|
31.1 M | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - |  Russia |
 |
AIkido Pharma
AIKI
|
-1.04 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-239 M | - | -0.23 % | $ 916 M | USA |
 |
Cellectis S.A.
CLLS
|
-206 M | $ 3.88 | - | $ 116 M | France |
 |
Allena Pharmaceuticals
ALNA
|
-29.5 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aileron Therapeutics
ALRN
|
-3.44 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-63.9 M | - | - | $ 2.17 B | USA |
 |
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M | Canada |
 |
Ampio Pharmaceuticals
AMPE
|
-12 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
-13.6 M | $ 3.1 | -0.44 % | $ 1.18 M | USA |
 |
Aravive
ARAV
|
-49.6 M | - | -13.39 % | $ 1.45 M | USA |
 |
Cocrystal Pharma
COCP
|
-8.05 M | $ 1.02 | -0.97 % | $ 10.4 M | USA |
 |
Aptose Biosciences
APTO
|
-5.53 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-33.8 M | - | -39.0 % | $ 4.57 M | USA |
 |
Collegium Pharmaceutical
COLL
|
-226 M | $ 42.0 | 0.79 % | $ 1.33 B | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
-114 M | $ 35.61 | -0.25 % | $ 3.7 B | USA |
 |
Athira Pharma
ATHA
|
-47.2 M | - | - | $ 269 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
-3.05 M | - | 17.91 % | $ 11.1 M | USA |